MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

Non-clear cell renal cell carcinoma: Management of papillary RCC

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

Bladder cancer updates from the first half of 2025

Treatment management of favourable risk and very favourable risk patients

The hidden biology of addiction and cancer

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

ASCO 2025: Importance of early testing in metastatic prostate cancer

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC